Project Grant HT94252510899
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $491K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- This Project Grant award of $735,751.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the University of Texas MD Anderson Cancer Center to develop a novel immunotherapy approach for the treatment of pancreatic cancer. The research aims to combine TROP2-directed chimeric antigen receptor (CAR) natural killer (NK) cells with hypoxia-inducible factor 2 alpha (HIF2a) inhibition, with the goal of...
- This $613,125 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of EGFRXHER3 bispecific CAR-T cells for targeting EGFR tyrosine kinase inhibitor drug-tolerant persister cells. The project will be performed by the University of Texas MD Anderson Cancer Center in Houston, TX over a period of 3 years from February 2025 to January 2028. The research aims to advance innovative therapeutic approaches...
- This federal Project Grant award of $566,998.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research targeting acute myeloid leukemia (AML) using a CD123-directed NK-cell engager and NK cell immune therapy, as well as harnessing the apoptotic machinery through BCL-2 inhibition. The project will be performed by the University of Texas MD Anderson Cancer Center in Houston, TX over a period from September 30, 2024 to...
- This Project Grant award of $718,858.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center in Houston, TX to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The project will run from February 15, 2025 to February 14, 2028, with the goal of advancing scientific understanding and potential clinical applications in this...
- This federal Project Grant award of $5,471,258.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting research conducted by the University of Texas MD Anderson Cancer Center in Houston, TX. The research project aims to investigate targeting the ganglioside GD2 as a potential approach to overcoming chemotherapy resistance in triple-negative breast cancer. The award period runs from September 1, 2025 through August 31, 2029. The...
- This Project Grant award for $536,186.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct research on APOBEC3A and its role in tumor evolution and intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC). The award will fund this research project over a 3-year period from Sep 30, 2023 to Sep 29, 2026. As...
- This federal Project Grant award of $1,348,314.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center. The funding supports a research project titled "BUILDING T-CELL PRODUCTS IN NF1-ASSOCIATED MPNST THROUGH ANTIGEN DISCOVERY AND EPIGENOME TARGETING". The project aims to conduct advanced biomedical research to transform healthcare for military service members,...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the "Discovery of Noncanonical Antigens in Triple-Negative Breast Cancer for Development of Novel T Cell Therapies" at the University of Texas MD Anderson Cancer Center in Houston, TX. The $505,071 award, made on February 15, 2025, will fund research aimed at identifying new cancer-specific antigens and developing innovative T cell-based immunotherapies...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,622,612.00 to The University of Texas M.D. Anderson Cancer Center to conduct preclinical research on novel combination therapeutic strategies targeting KRAS and BRAF mutated colorectal cancer. The goal is to validate these approaches for near-term clinical examination. The research will span from September 1, 2025 to August 31, 2028 and leverage M.D. Anderson's...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research at the University of Texas MD Anderson Cancer Center to investigate a novel therapeutic strategy for overcoming immunotherapy resistance in clear cell renal cell carcinoma (cCRCC). The $817,496 award, effective from September 1, 2025 to August 31, 2028, is focused on targeting the PRMT3-IGF2BP1 axis to understand epitranscriptomic reprogramming and...